UK markets close in 7 hours 21 minutes
  • FTSE 100

    7,749.41
    -15.74 (-0.20%)
     
  • FTSE 250

    19,899.15
    -136.24 (-0.68%)
     
  • AIM

    867.98
    -1.26 (-0.14%)
     
  • GBP/EUR

    1.1375
    -0.0029 (-0.25%)
     
  • GBP/USD

    1.2385
    -0.0010 (-0.08%)
     
  • BTC-GBP

    18,946.06
    +142.58 (+0.76%)
     
  • CMC Crypto 200

    532.06
    +15.06 (+2.91%)
     
  • S&P 500

    4,070.56
    +10.13 (+0.25%)
     
  • DOW

    33,978.08
    +28.68 (+0.08%)
     
  • CRUDE OIL

    79.08
    -0.60 (-0.75%)
     
  • GOLD FUTURES

    1,939.00
    -6.60 (-0.34%)
     
  • NIKKEI 225

    27,433.40
    +50.84 (+0.19%)
     
  • HANG SENG

    22,069.73
    -619.17 (-2.73%)
     
  • DAX

    15,089.76
    -60.27 (-0.40%)
     
  • CAC 40

    7,065.83
    -31.38 (-0.44%)
     

Embolotherapy Global Market - Forecast to 2029

ReportLinker
ReportLinker

Embolotherapy involves the percutaneous endovascular use of one or more of a variety of agents and has evolved as a minimally invasive procedure for controlling blood loss during complicated surgical procedures involving laparoscopic, neurovascular, uterine fibroids, arteriovenous malformations, hepatocellular carcinomas, benign prostate hyperplasia (BPH), neurovascular, intracranial and peripheral vasculatures related surgeries.

New York, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Embolotherapy Global Market - Forecast to 2029" - https://www.reportlinker.com/p06377911/?utm_source=GNW


According to IQ4I analysis, the Embolotherapy global market is expected to grow at mid single digit CAGR from 2022 to 2029 to reach $6,115.9 million by 2029. The Embolotherapy market is segmented based on products, applications, procedures, end-users and geography. The Embolotherapy products market is segmented into temporary agents, permanent agents, Radioembolization, and supporting devices, among them, permanent agents held the largest share of the market in 2022 and are expected to grow at high single digit CAGR from 2022 to 2029. The radioembolization segment is expected to grow at high single digit CAGR from 2022 to 2029. Temporary agents are further sub-segmented into autologous agents and Resorbable gelatin sponges, of this, the Resorbable gelatin sponge accounted for the largest share in 2022 and are expected to grow at mid single digit CAGR from 2022 to 2029. The permanent agents market is further sub-segmented into particle agents, coils, liquid embolization agents, flow diverters and others, among which the coils segment commanded the largest share in 2022 and is expected to grow at low single digit CAGR from 2022 to 2029. The liquid embolization agents market is expected to grow at early teens CAGR from 2022 to 2029. The particle agents are further segmented into poly vinyl alcohol (PVA) and microspheres, among which the microspheres segment commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The coils are further segmented into pushable and detachable coils among which the detachable coils commanded the largest share in 2022, the segment is expected to grow at low single digit CAGR from 2022 to 2029.

The applications market is segmented into neurology, oncology, peripheral vascular diseases, urology and others, among them, the neurology segment held the largest share of 44.5% in 2022 and is expected to grow at mid single digit CAGR from 2022 to 2029. The urology segment is expected to grow at high single digit CAGR from 2022 to 2029. The neurology application market is sub-segmented into the intracranial aneurysm and arteriovenous malformation (AVM), of this, the intracranial aneurysm segment command the largest revenue in 2022, the AVM segment is expected to grow at high single digit CAGR from 2022 to 2029. The oncology market is further sub-segmented into liver cancer, lung cancer, and others, of this, the lung cancer segment commanded the largest revenue in 2022 and the market is expected to grow at high single digit CAGR from 2022 to 2029.

Based on Procedures the embolotherapy global market is segmented into Transcatheter Arterial Embolization (TAE), Transcatheter Arterial Chemoembolization (TACE), and Transcatheter Arterial Radioembolization (TARE)/Selective Internal Radiation Therapy (SIRT), among them, TAE commanded the largest share in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029, the TARE/SIRT segmented is expected to grow at high single digit CAGR from 2022 to 2029. The Transcatheter Arterial Chemoembolization (TACE) market is segmented into drug-eluting beads-TACE and conventional TACE, among which the cTACE commanded the largest revenue in 2022 and the market is expected to grow at mid single digit CAGR from 2022 to 2029.

The end-users market is classified into hospitals, ambulatory surgical centers and others. Among them, the hospital commanded the largest share in 2022 and is expected to grow at high single digit CAGR from 2022 to 2029. The ambulatory surgical center is expected to grow at high single digit CAGR from 2022 to 2029.

Geographically, North America is the largest market, followed by Europe and the Asia Pacific. The APAC region is the fastest-growing region and is expected to grow at high single digit CAGR from 2022 to 2029 presenting an array of growth opportunities and is likely to get the attention of new investors in the Embolotherapy market. Growth in the Asian market is attributed to the rising prevalence of lifestyle diseases and government initiatives in establishing innovative technologies and demand for sophisticated medical services.

Factors such as the growing patient population with chronic conditions increasing the demand for embolization procedures, and technology advancements are driving the market growth, whereas, acquisitions and collaborations and emerging markets are providing growth opportunities.

On the other hand, side effects, complications, and risks associated with embolization and lack of skilled and trained professionals are restraining the market growth, while increasing product recalls, competition from alternative therapies and stringent regulatory requirements for product development and approvals are threatening the market growth.

The Embolotherapy global market is a highly competitive market and all the existing players in this market are involved in developing new and advanced products to maintain their market shares. Major players in the embolotherapy market include Medtronic, PLC (Ireland), Microport Scientific (China), Boston Scientific Corporation (U.S.), Stryker (U.S.), Terumo Corporation (Japan), Penumbra, Inc. (U.S.), Sirtex (CDH) (China), Johnson & Johnson (U.S.), Balt Group (France), Kaneka Corporation (Japan), Merit Medical (U.S.), Cook Medical (U.S.), Siemens Healthineers (Varian) (Germany), and Guerbet (France).
Read the full report: https://www.reportlinker.com/p06377911/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001